Clostridium difficile: Progress and challenges

John G. Bartlett

doi:10.1111/j.1749-6632.2010.05863.x

Clostridium difficile: Progress and challenges

John G. Bartlett

School of Medicine

Research output: Contribution to journal › Article › peer-review

76 Scopus citations

Abstract

There is a surge of new interest in C. difficile infection (CDI) reflecting substantial increases in cases and fatalities. The new challenges by this now old pathogen have brought renewed interest in all facets of the disease. Particularly important are the role of fluoroquinolones as inducing agents, the new polymerase chain reaction test to detect toxigenic strains in stools, the important role of the NAP-1 strain, recent evidence favoring oral vancomycin over metronidazole in seriously ill patients, and new guidelines for management.

Original language	English (US)
Pages (from-to)	62-69
Number of pages	8
Journal	Annals of the New York Academy of Sciences
Volume	1213
Issue number	1
DOIs	https://doi.org/10.1111/j.1749-6632.2010.05863.x
State	Published - Dec 2010

Keywords

Antibiotic-associated colitis
C. difficile
Clostridium difficile
Epidemiology
Fluoroquinolones
New guidelines, tests, and treatments
Oral vancomycin
Pseudomenbraneous colitis

ASJC Scopus subject areas

General Neuroscience
General Biochemistry, Genetics and Molecular Biology
History and Philosophy of Science

Access to Document

10.1111/j.1749-6632.2010.05863.x

Cite this

@article{60f3d2d83e8949838969995055e7a6bd,

title = "Clostridium difficile: Progress and challenges",

abstract = "There is a surge of new interest in C. difficile infection (CDI) reflecting substantial increases in cases and fatalities. The new challenges by this now old pathogen have brought renewed interest in all facets of the disease. Particularly important are the role of fluoroquinolones as inducing agents, the new polymerase chain reaction test to detect toxigenic strains in stools, the important role of the NAP-1 strain, recent evidence favoring oral vancomycin over metronidazole in seriously ill patients, and new guidelines for management.",

keywords = "Antibiotic-associated colitis, C. difficile, Clostridium difficile, Epidemiology, Fluoroquinolones, New guidelines, tests, and treatments, Oral vancomycin, Pseudomenbraneous colitis",

author = "Bartlett, {John G.}",

year = "2010",

month = dec,

doi = "10.1111/j.1749-6632.2010.05863.x",

language = "English (US)",

volume = "1213",

pages = "62--69",

journal = "Annals of the New York Academy of Sciences",

issn = "0077-8923",

publisher = "Wiley-Blackwell",

number = "1",

}

TY - JOUR

T1 - Clostridium difficile

T2 - Progress and challenges

AU - Bartlett, John G.

PY - 2010/12

Y1 - 2010/12

N2 - There is a surge of new interest in C. difficile infection (CDI) reflecting substantial increases in cases and fatalities. The new challenges by this now old pathogen have brought renewed interest in all facets of the disease. Particularly important are the role of fluoroquinolones as inducing agents, the new polymerase chain reaction test to detect toxigenic strains in stools, the important role of the NAP-1 strain, recent evidence favoring oral vancomycin over metronidazole in seriously ill patients, and new guidelines for management.

AB - There is a surge of new interest in C. difficile infection (CDI) reflecting substantial increases in cases and fatalities. The new challenges by this now old pathogen have brought renewed interest in all facets of the disease. Particularly important are the role of fluoroquinolones as inducing agents, the new polymerase chain reaction test to detect toxigenic strains in stools, the important role of the NAP-1 strain, recent evidence favoring oral vancomycin over metronidazole in seriously ill patients, and new guidelines for management.

KW - Antibiotic-associated colitis

KW - C. difficile

KW - Clostridium difficile

KW - Epidemiology

KW - Fluoroquinolones

KW - New guidelines, tests, and treatments

KW - Oral vancomycin

KW - Pseudomenbraneous colitis

UR - http://www.scopus.com/inward/record.url?scp=78650343594&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78650343594&partnerID=8YFLogxK

U2 - 10.1111/j.1749-6632.2010.05863.x

DO - 10.1111/j.1749-6632.2010.05863.x

M3 - Article

C2 - 21175676

AN - SCOPUS:78650343594

SN - 0077-8923

VL - 1213

SP - 62

EP - 69

JO - Annals of the New York Academy of Sciences

JF - Annals of the New York Academy of Sciences

IS - 1

ER -

Clostridium difficile: Progress and challenges

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this